Navigation Links
Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
Date:11/17/2010

ss cr="true" href="http://services.choruscall.com/links/resverlogix101117.html">http://services.choruscall.com/links/resverlogix101117.html. About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-l. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit href="http://www.resverlogix.com/">www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known an
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data
2. Resverlogix Appoints Kenneth J. Zuerblis to Board of Directors
3. Resverlogixs Phase 2 ASSURE Trial Amended
4. Resverlogix Scientific Data Presented at EAS Congress
5. Resverlogix Completes Dosing for ASSERT Trial
6. Resverlogix Notice of Conference Call & Webcast for Year End Update
7. Resverlogix Activates First Site for ASSURE 1 Clinical Trial
8. Resverlogix Completes Patient Recruitment for ASSERT Trial
9. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
10. Resverlogix Presenting at Biotech Showcase
11. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... (PRWEB) May 16, 2013 The ... by Global Cooling, Inc., Athens, OH, USA, won the ... by the International Society for Biological and Environmental Repositories ... award, given to one product annually, recognizes the company’s ... ultra-low temperature freezer. The award was presented to ...
(Date:5/16/2013)... 16, 2013 A new selection ... from Cole-Parmer is designed to meet the dynamic ... , The new Cole-Parmer® MS-3400 Centrifuges ... the lab. They ensure a powerful and complete ... separation. Their standard four-place swinging buckets hold 50-mL ...
(Date:5/16/2013)... SAN DIEGO , May 16, 2013  The ... the Association of Bioscience Financial Officers (ABFO) 2013 National Conference, ... will be held May 28-31 at the Hilton San ... finishing touches on this year,s conference and want to ... opportunity to attend," said Brandi Roberts ...
(Date:5/16/2013)... , May 16, 2013 /PRNewswire/ ... market research report is available in ... Competitor Analysis: Therapeutic Proteins ... http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical   ...   The new Competitive ...
Breaking Biology Technology:Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2Cole-Parmer Offers Enhanced Selection of Centrifuges 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8
... Inc., a biotechnology company delivering breakthrough therapies in central ... will be participating at two upcoming healthcare investor conferences. ... at the 2nd Annual BIO Venture Conference on April ... Hotel in Boston, MA. On April 9 at 11:30 ...
... Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; ... generation of monoclonal antibodies based on its Dynamic Cross ... Company has entered into a loan facility with a ... to USD$2.5 million. The loan facility, subject to final ...
... March 25 Human Genome Sciences, Inc. (Nasdaq: ... subsidiary of Eisai Corporation of North America, today ... to discover, develop and commercialize therapeutic monoclonal antibodies ... specifically target antigens discovered by HGS.(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ...
Cached Biology Technology:Accera, Inc. to Present at Upcoming Investor Conferences 2InNexus Biotechnology Announces a Loan Facility of up to USD$2.5 Million 2Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology 2Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology 3Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology 4Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology 5
(Date:5/16/2013)... scientists have shown a gene involved in neurodegenerative disease ... of the circadian clock. , In a study ... gene, called Ataxin-2, keeps the clock responsible for sleeping ... the rhythm of the fruit fly,s sleep-wake cycle is ... for the fly. , The discovery is particularly ...
(Date:5/16/2013)... 16, 2013 Integrated Biometrics patented LES ... custom thin film transistor camera introduces Sherlock, a ... image in the smallest and lightest form factor ... F Mobile ID FAP 45, Certified scanner is ... size and weight when compared to optical scanners. ...
(Date:5/16/2013)... neuroscientists from Canada and around the world are ... Canadian Neuroscience Meeting will showcase the latest in ... and reveal clues to understanding the disorders that ... research, and this meeting will showcase the best ... world," says Sam David, President of the Canadian ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2
... could create an evolutionary express lane that leads to the ... Pittsburgh and the University of Wisconsin at Madison have found. ... National Academy of Sciences ( PNAS ) that slight ... the when, where, and how much in gene productioncan activate ...
... University study has found that sunlight decreases the toxicity of ... United States every year. While golden algae is primarily ... and lakes, including Lake Whitney and Lake Waco in Central ... several environmental factors influence toxin production, but new research from ...
... Alexandria, VA The International and American Associations for ... symposium themed "Tissue Injury and Pulp Regeneration," held in ... the IADR Pulp Biology and Regeneration Group, and they ... Advances in Dental Research, an E-supplement to the ...
Cached Biology News:Leaky genes put evolution on the fast track, Pitt and UW-Madison researchers find 2IADR/AADR publish proceedings from Symposium on Tissue Injury and Pulp Regeneration 2
... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
Topoisomerase I...
...
Biology Products: